OBI Pharma Earns Sports Enterprise Certification Again
Building a Healthy Workplace and Fulfilling Sustainability Commitments

Key Technologies + Innovative Products + Flexible Business Models
Dr. Heidi Wang: Shaping OBI Pharma into a Leading and Thriving Global Biotech Company

OBI Pharma Showcases Biomarker Innovations at Singapore APAC Summit
Precision Medicine Tools Drive Success in New Drug Development

OBI-992 Ranks Among World ADC Award Top 8, Stands Strong Among Global Pharma Giants Despite Missing Top Prize, Gains Global Recognition

OBI Pharma Invited to Speak at World ADC Conference Innovative Linker Technology and GlycOBI® ADC Platform Capture Global Attention

OBI Pharma to Showcase Research Achievements and Cutting Edge ADC Platform Technology
Frequent Speaking Engagements at Prestigious International Conferences

OBI Pharma and Fu Jen Catholic University Sign Industry-Academia Collaboration MOU
Advancing Biotechnology Innovation and Developing Young Talent

OBI volunteers at a breast cancer patient event Showcasing our commitment to patients and to new drug development.

Ascentawits Pharma announced the interim analysis results of the AST-3424 Phase II clinical efficacy and safety study in advanced HCC at the 2024 CSCO conference

OBI-992 Shortlisted as the Most Promising Clinical Candidate in the 11th Annual World ADC Awards